Clinical Trials Detail - University of Colorado Hospital

Skip to Content

Research

Clinical Trials

Search for

in

In Progress (12)

Showing 1-10 of 12

Sorted By:

A-Z
Z-A

A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100
An Open-Label Multicenter Study in Metastatic Castrate-Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11.
BNIT-PRV-301. A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ¦ GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer.
CALGB C90203: Randomized phase III study of neo-adjuvant Docetaxel and Androgen deprivation prior to radical prostatectomy vs immediate radical prostatectomy in patients with high risk clinically localized prostate cancer.
CALGB-C70807; The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
Phase II open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy
RTOG 0526 A PROSPECTIVE PHASE II TRIAL OF TRANSPERINEAL ULTRASOUND-GUIDED BRACHYTHERAPY FOR LOCALLY RECURRENT PROSTATE ADENOCARCINOMA FOLLOWING EXTERNAL BEAM RADIOTHERAPY
RTOG 0534 A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY
RTOG 0815 A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER

Go to Page Page of 2, showing trials 1-10 of 12